High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance

Following CART-19 immunotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), many patients relapse due to loss of the cognate CD19 epitope. Since epitope loss can be caused by aberrant CD19 exon 2 processing, we herein investigate the regulatory code that controls CD19 splicing. We combine high...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortés-López, Mariela, Schulz, Laura, Enculescu, Mihaela, Paret, Claudia, Spiekermann, Bea, Quesnel-Vallières, Mathieu, Torres-Diz, Manuel, Unic, Sebastian, Busch, Anke, Orekhova, Anna, Kuban, Monika, Mesitov, Mikhail, Mulorz, Miriam M., Shraim, Rawan, Kielisch, Fridolin, Faber, Jörg, Barash, Yoseph, Thomas-Tikhonenko, Andrei, Zarnack, Kathi, Legewie, Stefan, König, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500061/
https://www.ncbi.nlm.nih.gov/pubmed/36138008
http://dx.doi.org/10.1038/s41467-022-31818-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500061/
https://www.ncbi.nlm.nih.gov/pubmed/36138008
http://dx.doi.org/10.1038/s41467-022-31818-y

Ejemplares similares